GlassScriptPhysician profile
Raju Rao
NPI 1053315648
$11,666.48
in general payments reported to CMS, 2019-2025
71 companies · $2,683 in 2025
The $2,683 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,295 · 2020: $449 · 2021: $870 · 2022: $1,198 · 2023: $2,513 · 2024: $2,660 · 2025: $2,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,798 · Education: $57.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,797.91 |
| Education | $57.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $949.92 | 2019-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $845.88 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $659.47 | 2019-2025 | Reblozyl, Opdualag |
| Novartis Pharmaceuticals Corporation | $554.88 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $514.09 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| Pfizer INC. | $475.15 | 2019-2025 | |
| Janssen Biotech, INC. | $438.75 | 2019-2025 | Rybrevant, Erleada, Talvey |
| Incyte Corporation | $438.61 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Genzyme Corporation | $394.83 | 2019-2025 | |
| Lilly USA, LLC | $390.59 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $383.68 | 2019-2025 | |
| Genentech USA, INC. | $382.29 | 2019-2025 | Tecentriq, Alecensa, Polivy |
| Gilead Sciences, INC. | $338.31 | 2021-2025 | Trodelvy |
| Seagen INC. | $316.88 | 2019-2023 | Padcev, Tukysa, Adcetris |
| Astellas Pharma US INC | $295.57 | 2019-2025 | Padcev, Xospata, Xtandi |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $267.60 | 2019-2022 | |
| Glaxosmithkline, LLC. | $262.32 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Daiichi Sankyo INC. | $225.49 | 2022-2025 | Enhertu, Datroway, Vanflyta |
| Csl Behring | $206.57 | 2022-2025 | Afstyla, Idelvion, Hemgenix |
| Eisai INC. | $205.38 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $203.23 | 2019-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $196.81 | 2023-2025 | Alunbrig, Fruzaqla |
| Alexion Pharmaceuticals, INC. | $176.47 | 2019-2025 | Ultomiris |
| Puma Biotechnology, INC. | $171.41 | 2021-2025 | |
| G1 Therapeutics, INC. | $160.28 | 2022-2023 | Cosela |
| Array Biopharma INC | $151.12 | 2019-2025 | Braftovi, Mektovi, Tukysa |
| Aveo Pharmaceuticals, INC. | $136.34 | 2021-2025 | Fotivda |
| Janssen Pharmaceuticals, INC | $102.10 | 2019-2024 | Xarelto |
| Legend Biotech USA INC. | $99.60 | 2025 | Carvykti |
| Abbvie INC. | $95.34 | 2019-2025 | |
| Pharmacosmos Therapeutics INC. | $92.72 | 2023-2025 | Monoferric, Cosela |
| Stemline Therapeutics INC. | $89.07 | 2023-2025 | Orserdu |
| Jazz Pharmaceuticals INC. | $73.80 | 2021-2024 | |
| Emd Serono, INC. | $70.16 | 2023 | Bavencio |
| Agios Pharmaceuticals, INC. | $66.85 | 2019-2025 | Pyrukynd |
| Sobi, INC | $66.01 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $64.56 | 2024-2025 | Orgovyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.79 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $58.35 | 2020-2023 | Xpovio |
| Tempus Ai, INC | $56.29 | 2024 | Xt Cdx |
| Sun Pharmaceutical Industries INC. | $52.56 | 2022-2025 | Yonsa, Odomzo |
| Adc Therapeutics America, INC. | $51.64 | 2024-2025 | |
| Genmab U.S., INC. | $50.28 | 2023-2024 | Epkinly |
| Geron Corporation | $48.86 | 2025 | Rytelo |
| Rigel Pharmaceuticals, INC. | $47.61 | 2023-2024 | Tavalisse, Rezlidhia |
| Mirati Therapeutics, INC. | $45.76 | 2023-2024 | Krazati |
| Kite Pharma, INC. | $45.05 | 2023-2025 | Yescarta |
| Deciphera Pharmaceuticals INC. | $40.20 | 2021 | |
| Partner Therapeutics, INC. | $38.42 | 2019 | |
| Kyowa Kirin, INC. | $37.81 | 2021-2024 | Poteligeo |
| Cti Biopharma Corp. | $37.70 | 2023 | Vonjo |
| Aurobindo Pharma USA, INC. | $36.62 | 2019-2020 | |
| Myovant Sciences INC. | $35.10 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $33.45 | 2025 | Enjaymo |
| Beone Medicines USA, INC. | $27.01 | 2025 | Brukinsa |
| Servier Pharmaceuticals LLC | $25.04 | 2024 | |
| Fennec Pharmaceuticals, INC. | $24.11 | 2024 | Pedmark |
| Teva Pharmaceuticals USA, INC. | $24.04 | 2019 | |
| Pharmaessentia USA Corporation | $22.77 | 2024 | Besremi |
| Ipsen Biopharmaceuticals, INC | $21.49 | 2024 | Somatuline Depot, Onivyde |
| Global Blood Therapeutics, INC. | $20.95 | 2021 | |
| Amag Pharmaceuticals, INC. | $19.88 | 2019 | |
| Tersera Therapeutics LLC | $19.38 | 2019 | |
| Morphosys, US INC. | $19.34 | 2023 | Monjuvi |
| Pharmacyclics LLC, An Abbvie Company | $18.65 | 2019 | |
| Alnylam Pharmaceuticals INC. | $18.25 | 2023 | Givlaari |
| Beigene USA, INC. | $15.45 | 2022 | |
| Alfasigma USA, INC. | $14.06 | 2020 | |
| Advanced Accelerator Applications | $13.38 | 2020 | |
| Taiho Oncology, INC. | $13.16 | 2019 | |
| Veracyte, INC. | $9.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raju Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.